During the last three years, ResMed increased its R&D investments from $63.1 million in 2009 to $92 million in 2011.

The company continually seeks to identify new applications of its technology for significant unmet medical needs and is supporting clinical trials in many countries, including the US, Germany, France, UK, Italy Switzerland, China and Australia, to develop new clinical applications of its technology.

Dr Peter C Farrell, president and CEO, ResMed, pointed out that increasing awareness of the dangers of untreated sleep-disordered breathing is the prime agenda of ResMed. The company is enhancing the benchmark for effective diagnosis, therapy, patient comfort and compliance.